{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:58:49Z","timestamp":1793303929721,"version":"4.5.0"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,5,1]]},"DOI":"10.1001\/jamaoncol.2019.6650","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T11:31:04Z","timestamp":1581593464000},"page":"676","source":"Crossref","is-referenced-by-count":674,"title":["Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer"],"prefix":"10.1001","volume":"6","author":[{"given":"Rita","family":"Nanda","sequence":"first","affiliation":[{"name":"The University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minetta C.","family":"Liu","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Yau","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Shatsky","sequence":"additional","affiliation":[{"name":"University of California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Pusztai","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Wallace","sequence":"additional","affiliation":[{"name":"University of California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Jo","family":"Chien","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Forero-Torres","sequence":"additional","affiliation":[{"name":"University of Alabama, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Ellis","sequence":"additional","affiliation":[{"name":"Swedish Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Han","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Clark","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Albain","sequence":"additional","affiliation":[{"name":"Loyola University Chicago Stritch School of Medicine, Maywood, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy C.","family":"Boughey","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora T.","family":"Jaskowiak","sequence":"additional","affiliation":[{"name":"The University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Elias","sequence":"additional","affiliation":[{"name":"University of Colorado, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Isaacs","sequence":"additional","affiliation":[{"name":"Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Kemmer","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Helsten","sequence":"additional","affiliation":[{"name":"University of California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Majure","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Stringer-Reasor","sequence":"additional","affiliation":[{"name":"University of Alabama, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Parker","sequence":"additional","affiliation":[{"name":"The University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C.","family":"Lee","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tufia","family":"Haddad","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Cohen","sequence":"additional","affiliation":[{"name":"The University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Asare","sequence":"additional","affiliation":[{"name":"Quantum Leap Healthcare Collaborative, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Wilson","sequence":"additional","affiliation":[{"name":"Quantum Leap Healthcare Collaborative, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian L.","family":"Hirst","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Singhrao","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Steeg","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Asare","sequence":"additional","affiliation":[{"name":"Quantum Leap Healthcare Collaborative, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Matthews","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Berry","sequence":"additional","affiliation":[{"name":"Berry Consultants, LLC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Sanil","sequence":"additional","affiliation":[{"name":"Berry Consultants, LLC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Schwab","sequence":"additional","affiliation":[{"name":"University of California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Fraser","family":"Symmans","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"van \u2018t Veer","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Yee","sequence":"additional","affiliation":[{"name":"University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"DeMichele","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nola M.","family":"Hylton","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Melisko","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Perlmutter","sequence":"additional","affiliation":[{"name":"Gemini Group, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A.","family":"Berry","sequence":"additional","affiliation":[{"name":"Berry Consultants, LLC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Esserman","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"coi190112r1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152500","article-title":"The prognostic value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis.","volume":"11","author":"Mao","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"coi190112r2","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317695023","article-title":"Tumor-infiltrating lymphocytes and breast cancer: beyond the prognostic and predictive utility.","volume":"39","author":"Ravelli","year":"2017","journal-title":"Tumour Biol"},{"issue":"1","key":"coi190112r3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"coi190112r4","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda).","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"21","key":"coi190112r5","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study.","volume":"34","author":"Nanda","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi190112r6","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-17-3452","article-title":"Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer.","volume":"24","author":"Rugo","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"coi190112r7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"coi190112r8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"issue":"22","key":"coi190112r9","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1200\/JCO.2008.18.5397","article-title":"Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.","volume":"27","author":"Gradishar","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi190112r10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.","volume":"19","author":"Asselain","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi190112r11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1513750","article-title":"Adaptive randomization of neratinib in early breast cancer.","volume":"375","author":"Park","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"coi190112r12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1513749","article-title":"Adaptive randomization of veliparib-carboplatin treatment in breast cancer.","volume":"375","author":"Rugo","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"coi190112r13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrclinonc.2011.165","article-title":"Adaptive clinical trials in oncology.","volume":"9","author":"Berry","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"coi190112r14","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.molonc.2015.02.011","article-title":"The brave new world of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research.","volume":"9","author":"Berry","year":"2015","journal-title":"Mol Oncol"},{"issue":"1","key":"coi190112r15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/clpt.2009.68","article-title":"I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.","volume":"86","author":"Barker","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"coi190112r16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group.","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"8","key":"coi190112r17","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer.","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"coi190112r18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.6004\/jnccn.2017.0044","article-title":"NCCN guidelines insights: breast cancer, version 1.2017.","volume":"15","author":"Gradishar","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"28","key":"coi190112r19","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi190112r20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/1471-2164-7-278","article-title":"Converting a breast cancer microarray signature into a high-throughput diagnostic test.","volume":"7","author":"Glas","year":"2006","journal-title":"BMC Genomics"},{"issue":"22","key":"coi190112r21","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-09-0449","article-title":"Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.","volume":"15","author":"Roepman","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"9938","key":"coi190112r22","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"coi190112r23","article-title":"Analysis of immune infiltrates (assessed via multiplex fluorescence immunohistochemistry) and immune gene expression signatures as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 trial (Abstract PD6-08).","volume":"78","author":"Campbell","year":"2018","journal-title":"Cancer Res"},{"key":"coi190112r24","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.003","article-title":"Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC).","volume":"30","author":"Schmid","year":"2019","journal-title":"Annals Oncol"},{"issue":"2","key":"coi190112r25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis.","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2761193\/jamaoncology_nanda_2020_oi_190112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T23:32:24Z","timestamp":1589499144000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2761193"}},"subtitle":["An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial"],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.6650","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}